Kieffer Tara Lynn 4
4 · ENANTA PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Enanta (ENTA) Chief Product Strategy Officer Tara Kieffer Receives Award
What Happened
Tara Lynn Kieffer, Enanta Pharmaceuticals' Chief Product Strategy Officer, received 6,562 shares of Enanta common stock on Feb 12, 2026 from the settlement of performance-based awards (1,575 shares and 4,987 shares). Those awards were issued at $0.00 per share (award settlement). To cover withholding taxes on the vesting, 3,257 shares were automatically forfeited (disposed) at a valuation of $14.25 per share, totaling $46,412. Net shares issued to Kieffer after withholding: 3,305 shares. This was the settlement of awards (not an open-market purchase or voluntary sale).
Key Details
- Transaction date: February 12, 2026; Form 4 filed Feb 13, 2026 (timely).
- Awards issued: 1,575 shares (PSUs) + 4,987 shares (rTSRU) = 6,562 shares at $0.00 acquisition price.
- Tax withholding: 3,257 shares withheld/disposed at $14.25 = $46,412.
- Net shares received: 3,305.
- Shares owned after transaction: not disclosed in this filing.
- Footnotes: F1 = PSUs vested based on 2024–2025 R&D milestones; F2 = rTSRU settled based on relative total shareholder return vs. Nasdaq Biotech Index; F3 = shares automatically forfeited to cover withholding taxes.
- Transaction codes: A = award/grant; F = tax withholding/settlement.
Context
These were performance-based equity awards that vested and were settled in stock — common executive compensation rather than an open-market buy or sale. The rTSRU is a relative-TSR award tied to performance versus the Nasdaq Biotech Index over two-year periods; the PSU was tied to R&D milestones. Automatic share forfeiture to cover taxes is routine and does not necessarily indicate a discretionary sale by the insider.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-12+1,575→ 32,195 total - Award
Common Stock
[F2]2026-02-12+4,987→ 37,182 total - Tax Payment
Common Stock
[F3]2026-02-12$14.25/sh−3,257$46,412→ 33,925 total
Footnotes (3)
- [F1]Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F2]Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F3]Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.